Embecta Corp. is a healthcare company that focuses on the development and manufacturing of products for people living with diabetes. The company specializes in diabetes management solutions, including insulin delivery systems and other related devices, aimed at improving the quality of life for patients. With a commitment to innovation, Embecta aims to enhance the safety and efficiency of diabetes care, ultimately contributing to better health outcomes for individuals managing this chronic condition. Its comprehensive portfolio is designed to address the diverse needs of users, from novice patients to experienced individuals, ensuring accessible and effective technologies in diabetes therapy. Read More
Bragar Eagel & Squire, P.C.��Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Embecta (EMBC) To Contact Him Directly To Discuss Their Options
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Embecta To Contact Him Directly To Discuss Their Options
NEW YORK, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Embecta Corp. (“Embecta” or the “Company”) (NASDAQ: EMBC) on behalf of investors that purchased or otherwise acquired Embecta securities between November 25, 2025 and May 4, 2026 (the “Class Period”).
Rosen Law Firm, a global investor rights law firm, reminds investors about a class action lawsuit on behalf of purchasers of common stock of Embecta Corp. (NASDAQ: EMBC) between November 25, 2025 and May 4, 2026. Embecta describes itself as a “leading global medical device company focused on providing solutions to improve the health and well-being of people living with diabetes.”
LOS ANGELES, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Embecta Corp. (“Embecta” or “the Company”) (NASDAQ: EMBC) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
NEW YORK, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Embecta Corp. (“Embecta” or the “Company”) (NASDAQ: EMBC) on behalf of investors that purchased or otherwise acquired Embecta securities between November 25, 2025 and May 4, 2026 (the “Class Period”).
NEW YORK, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds Embecta Corp. (“Embecta” or the “Company”) (NASDAQ: EMBC) investors of the August 17, 2026 deadline involving a securities fraud class action lawsuit commenced against the Company.
NEW YORK, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Embecta Corp. (“Embecta” or the “Company”) (NASDAQ: EMBC). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Embecta (EMBC) To Contact Him Directly To Discuss Their Options
NEW YORK, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Embecta Corp. (“Embecta” or the “Company”) (NASDAQ: EMBC) on behalf of investors that purchased or otherwise acquired Embecta securities between November 25, 2025 and May 4, 2026 (the “Class Period”).
LOS ANGELES, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Embecta Corp. (“Embecta” or “the Company”) (NASDAQ: EMBC) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Embecta (NASDAQ:EMBC) reported fiscal third-quarter 2026 revenue of approximately $272 million, down 8.1% from the prior-year period on a reported basis and down 8.9% on an adjusted constant-currency basis. The company said results improved sequentially from the fiscal second quarter, with revenue r
LOS ANGELES, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Embecta Corp. (“Embecta” or “the Company”) (NASDAQ: EMBC) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
NEW YORK, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Embecta Corp. (“Embecta” or the “Company”) (NASDAQ: EMBC). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
